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ABSTRACT

Abrefa, Darlington Osei. M.S., Microbiology and Immunology graduate program, Wright
State University, 2019. Genetic Study of Checkpoint Defects of the Mus81-1 Mutant in the
Fission Yeast Schizosaccharomyces Pombe.

In response to various perturbations of DNA replication, the DNA replication checkpoint is
activated in eukaryotes to stimulate a cascade of cellular responses that are crucial for
maintaining genome stability and cell survival. Defects in the checkpoint pathway result in
mutations and genome instability, which is a hallmark for cancers. This study used a genetic
approach to identify a mutation in the MMS (methyl methanesulfonate) and UV-sensitive
protein Mus81, a DNA repair enzyme that resolves aberrant DNA structures through the
homologous recombination pathway. We show that a single missense mutation, identified in
fission yeast mus81-1, causes moderate reduction in the phosphorylation levels of the major
DNA replication checkpoint proteins Mrc1(Claspin) and Cds1(Chk2) in fission yeast. We also
show that the mutation directly affects the DNA repair and the DNA damage checkpoint
mediated by Chk1 that causes dramatic cell lethality in mus81-1 mutant upon treatment with
the DNA damaging agents: MMS, UV and Bleomycin.
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INTRODUCTION

CHECKPOINT SIGNALING PATHWAYS
The cell cycle is a highly regulated process in the cell during which DNA is duplicated
followed by division of the cell and organelles. The most important stage of the cell cycle, S
phase where DNA duplication takes place must be completed with high fidelity to ensure
genome stability (Burhans, Carr & Wahl, 2006). Inefficient completion of this phase results
in under replication of the genome and unhealthy cells after mitotic division. DNA replication
is however constantly under attack by factors of both endogenous and exogenous sources
including depletion of nucleotides, inhibition of polymerase activity or damage to the DNA
template resulting in fork stalling (McGowan & Russell, 2014; Tsang & Carr, 2008). Stalled
forks, if unresolved properly, can lead to chromosomal aberrations or even cell death (Ciccia
& Elledge, 2010). Eukaryotes have evolved regulated mechanisms including the cell cycle
checkpoint that functions as a surveillance mechanism that monitors cell cycle progression to
ensure that each phase of the cell cycle is completed with accuracy and precision before
moving to the next phase of the cell cycle (Boddy, 1999; Sasi & Weinreich, 2016). The two
most studied cell cycle checkpoints in the fission yeast Schizosaccharomyces pombe are the
DNA replication checkpoint (DRC) and the DNA damage checkpoint (DDC). The DRC
monitors the progress of replication forks during normal S phase or under replication stress
(Rhind & Russell, 2010; Yue et al., 2011; Boddy, 1999; Ait Saada et al., 2017). In response
to DNA damage at the G2 phase, the DDC is activated to halt mitosis so that the cells have
enough time to properly repair the DNA damage. It is important to note that whiles the DRC
only slows the S phase, the DDC may completely arrest cell cycle upon DNA damage such
1

as strand breaks (Boe et al., 2012 & Boddy, 1999).
The DNA checkpoint pathways consist of three main functional units; sensors, mediators and
effectors. Sensors detect damaged DNA or stalled replication forks, mediators serve as signal
transducers that amplifies the checkpoint signal, and the effectors elicit the protective cellular
responses such as induction of apoptosis, DNA repair, halting cell cycle progression or
increase in production of deoxyribonucleotide triphosphates (dNTPs) (Yue et al., 2011).

Figure 1. The checkpoint signaling pathways in the fission yeast S. pombe. In an event of
fork perturbation at the S phase, Rad3 (ATR in mammalian cells) the major sensor kinase
complexes with its subunit Rad26 (ATRIP in mammalian cells) is activated. The 9-1-1
complex consisting of Rad1, Rad 9 and Hus1 (Table 1) is also loaded at the site of the stalled
fork through a clamp holder, Rad 17 which is related to the Rfc1 in loading the proliferating
cell nuclear antigen (PCNA) (Bermudez et al., 2010; Ellison et al., 2003). Rad3 begins the
DRC signaling after successful recruitment of the above mentioned sensors to the stalled
replication site. Rad3 first activates the mediator Mrc1 (Claspin in human cells) which induces
2

the downstream phosphorylation of Cds1 (CHK2 in human cells), the effector kinase for the
DRC (Tanaka & Russell, 2001; Xu, Davenport & Kelly, 2006). If the DNA damage occurs
outside S phase, Rad3 activates the DDC by activating the mediator Crb2 (53BP1 in human
cells) which facilitates the phosphorylation of Chk1, the effector kinase for the DDC
(Nakamura et al., 2004; Saka et al., 1997).
Understanding the mechanisms of checkpoint defects is critical not only in cell cycle
regulation but also for studying cell proliferation and genetic diseases, most notably cancer
(DePamphilis, 2006; Burhans et al., 2006).
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Table 1: Conserved checkpoint proteins in eukaryotes.
Function

S. pombe

Sensors

Rad3

Mediators

Effectors

Human

S. cerevisiae

ATR

Mec1

Tel1

ATM

Tel1

Rad26 (Rad3 subunit)

ATRIP

Ddc2

Rad17 (“9-1-1” loader)

hRAD17

Rad24

Rad9

hRAD9

Ddc2

Rad1

hRAD1

Rad17

Hus1

hHUS1

Mec3

Mrc1

Claspin

Mrc1

Crb2

53BP1

Rad9

Cds1

hCHK2

Rad53

Chk1

hCHK1

Chk1

PIKK

(Bermudez et al., 2003; Tsang & Carr, 2008; Boe et al., 2012)
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Methyl methane sulfonate (MMS), and UV-sensitive protein Mus81
In an attempt to restore stalled replication fork, a nearby origin can be fired to continue the
stalled replication. An alternative mechanism used by the cell to restore stalled fork is through
the homologous recombination (HR) pathway mediated by Mus81 (Brambati et al., 2018
; Yekezare, Gomez-Gonzalez & Diffley, 2013). Mus81 resolves the four-way DNA junction
formed during HR, by nicking the Holliday junctions and recombining the DNA duplexes
before chromosome segregation (Wyatt et al., 2014) (Figure 2). Aberrant chromosome
structures that result from perturbed forks are thus resolved through Mus81 complex. Mus81
belongs to a family of structure-specific endonucleases (SSEs) that catalyze endonucleolytic
cleavage at Holliday junctions, which is explained as a single-stranded crossover between two
homologous DNA duplexes (Chen et al., 2001; Smith et al., 2003) (Figure 2). Defects in this
pathway cause instability of the genome and cancers (Ait Saada, Lambert S-Silva & Carr,
2018 ; Mayle et al., 2015).

In human cells, Mus81 not only functions to resolve recombination intermediates (Chen et
al., 2001; Wyatt et al., 2013), it also functions in telomere maintenance and replication fork
restart (Hanada et al., 2007). A recent study however shows that the enzymatic activity of the
Mus81 complex inhibits fork restart in S phase because the endonuclease activity is decreased
in S phase and only increases in G2/M (Mayle et al., 2015). In contrast, another study proposes
that Mus81 is actively involved in S phase where it recruits Cds1 to aberrant DNA structures
(Boddy et al., 2000).

Although the role of Mus81 in chemotherapy is largely unknown, knockdown of Mus81 has
been reported to improve chemosensitivity in colon cancer and hepatocellular carcinoma
cells through S phase arrest and apoptosis via the Chk1 pathway (Wu et al., 2016; Wu et al.,
5

2017). Inhibition of Mus81 has also been reported to sensitize ovarian cancer cells to
chemotherapy by promoting apoptosis (Zhong et al., 2019). Downregulation of Mus81 may
thus be used as a prognostic biomarker for early cancer detection and for cancer treatment
(Wu et al., 2011).

Genetic and physical interactions of Mus81

Mus81 binds to Eme1 in S. pombe to form Mus81-Eme1 complex (Figure 2) (Boddy et al.,
2001). It physically interacts with Cds1, the effector kinase for the DRC (Boddy et al., 2000;
Kai et al., 2005) and genetically interacts with Chk1 and Crb2 in the DDC pathway (Boddy
et al., 2000; Kanoh et al., 2003). In S. cerevisiae, Mus81 binds to the protein named Mms4 to
form the Mus81-Mms4 endonuclease (de los Santos et al., 2003). In humans, it binds two
proteins namely; Eme1 and Eme2 to form Mus81-Eme1 and Mus81-Eme2 complexes with
both exhibiting similar biochemical properties (Pepe & West, 2014).

The agents used in this study that activate the DNA Replication Checkpoint
The agents that disrupt DNA replication were used in this study to activate the DNA
replication checkpoint and help understand if the mutant used in this study has a defective
checkpoint gene. These agents include hydroxyurea (HU) that depletes deoxyribonucleotide
triphosphates (dNTPs), methyl methane sulfonate (MMS), an DNA alkylating agent that alters
bases in the template, ultraviolet (UV) light that forms abnormal covalent bond between
adjacent pyrimidine bases, camptothecin (CPT) that locks topoisomerase I covalently onto
the DNA, and bleomycin (BLM) that induces single and double stranded breaks (Zeman &
Cimprich, 2014; D’Urso et al., 1999; Zhao et al., 2003).
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(Wyatt et al., 2014)

Figure 2: Role of Mus81-Eme1 complex in cell cycle progression.
Mus81-Eme1 complex resolves the four-way DNA junction formed during HR, by nicking
the Holliday junctions (pointed arrows) and recombining the DNA duplex before
chromosome segregation.
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(Gwon et al., 2014)
Figure 3: Crystal structure of human Mus81 complex.
A. Mus81 complex bound to a 5’ flap DNA. The nuclease and nuclease-like domains are on
top of the EHhH2 and MHhH2 domains, respectively. Substrate duplex DNA is shown with
green and orange backbone. The 5’ end binding pocket is shown with blue dotted circle. The
wedge is highlighted as black dotted circle
B. Mus81 complex bound to a 3′ flap DNA. Cleavage site is marked with an arrow and size
of the crystallized DNA is shown in black. Substrate DNA is shown in orange.
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Study model: the fission yeast Schizosaccharomyces pombe
Fission yeast is an established model for studying the cellular mechanisms that are conserved
in humans. Unlike human cells, fission yeast has a much shorter cell cycle time of 2-3 hours.
It can be easily manipulated that allows tracking of DNA damage and replication stalling in
S. pombe. It also has highly conserved checkpoint proteins (Table 1) allowing for
identification and characterization of mutated genes to help understand genetic diseases
conditions in humans. Lastly DNA damage and replication stalling can easily be studied by
microscopy with this organism. This organism therefore provides powerful genetic, genomic,
molecular, and biochemical tools for checkpoint and cancer research.
HYPOTHESIS
The mutation(s) in the newly screened SN106 mutant may have a checkpoint defect which
results in genome instability and cell death under stress.
MAIN OBJECTIVE
1. Characterize the newly screened SN106 mutant.
SPECIFIC OBJECTIVES
1. Confirm the drug sensitivity of the SN106 mutant.
2. Identify the mutation and mutated gene.
3. Examine the potential checkpoint defects.
4. Determine if overexpression of checkpoint proteins can rescue the SN106 mutant.
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MATERIALS AND METHODS
Yeast Strains, Plasmids and Chemicals
Standard methods and genetic techniques were used for the S. pombe cell culture and the
genetic screening. The S. pombe strains were usually cultured at 30°C in YE6S (0.5% yeast
extract, 3% dextrose and the 6 essential supplements, adenine, uracil, histidine, lysine,
leucine, and arginine) or in EMM medium lacking the appropriate supplements following
standard methods. Malt extract (ME) medium with 4 supplements was used for mating
purposes. MMS was used directly from the 99% stock solution (Sigma). HU (Sigma) was
prepared as a 1.0 M stock solution in distilled water. Phloxin B dye was used as an indicator
of cell lethality.
The collection of checkpoint mutants was derived from the wild type S. pombe YJ374 strain.
The SN106 mutant was kindly provided by Dr. Saman Khan. The yeast strains, plasmids, and
PCR primers used in this study are listed in Table 2, 3, and 4, respectively.
Drug Sensitivity Test
Drug sensitivity test for the mutants was performed by standard spot assay. 2 x 107 cells/ml
of logarithmically growing S. pombe were diluted in 3-fold or 6-fold steps and spotted in 3 µl
onto YE6S plates containing HU, MMS, BLM or CPT at the indicated concentrations in
figures 4, 5 and 7. The cells spotted on YE6S plates were also treated with UV (Stratalinker
2400). The plates were incubated at 30°C for 3 days and then photographed. Wild type cell
was used as negative control while chk1Δ and rad3Δ, cds1Δ, and rhp51Δ cells were used as
positive controls.
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Immunoprecipitation (IP)
Logarithmically growing cells were harvested and saved at -20˚C in a screw cap tube. The
frozen cell pellets were lysed by mini-bead beater in the buffer containing 25 mM
HEPES/NaOH (pH7.5), 50 mM NaF, 1 mM Na3VO4, 10 mM NaP2O7, 40 mM ßglycerophophate, 0.1% Tween 20, 0.5% NP-40, and protease inhibitors. The cell extract was
incubated with anti-HA antibody beads by rotating in 2 ml tubes at 4˚C for 2 hrs. The beads
were prewashed with TBS-T at 4˚C overnight. The samples were separated by SDS-PAGE
followed by Western blotting. The blotting signal was detected by electrochemiluminescence
using ChemiDoc XRS Imaging system (BioRad). Intensities of the bands were quantified and
analyzed by ImageLab (BioRad).

Western blotting analyses of phosphorylated Mrc1, Cds1 and Chk1
For examination of Mrc1 phosphorylation, logarithmically growing cells were fixed in 15%
trichloroacetic acid (TCA) on ice for ≥ 3h and then lysed by mini-bead beater. The lysates
from 2 - 4 x 106 cells were separated by SDS-PAGE and detected in the whole cell lysates by
Western blotting using phospho-specific antibody that detects phosphorylated Thr645 in Mrc1.
The same blot was striped and then blotted with anti-Mrc1 antibodies to detect Mrc1 protein.
Ponceau S staining was used as the loading control. For the examination of phosphorylated
Cds1 and Chk1, the two proteins were tagged with myc or HA epitope at their genomic loci.
The two proteins were IPed with anti-myc or anti-HA beads and then analyzed by Western
blotting.
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Flow cytometry
0.5 OD logarithmically growing cells were collected, fixed in 1ml of ice-cold 70% ice-cold
ethanol and store for 2 h. 0.3 ml of the fixed cells was then transferred in a new tube, pulse
spin to discard the supernatant. 0.5 ml 50 mM Na-Citrate with 0.1mg/ml RNase A was added
and incubated for 2 h. Before the analysis, 0.5 ml 50mM Na-Citrate with 4µg/ml PI was added.
The samples were immediately analyzed by Accuri C6 flow cytometer. Data was analyzed
using ‘FCS Express 4’ software.

Microscopy
The cells were fixed directly onto uncoated glass slides by heating briefly at 98˚C for 2
mins. Blankophor and Hoechst working solutions were prepared. 2 µl each these prepared
solutions were spread on the dried plates. The stained cells were examined using an
Olympus EX41 fluorescent microscope. Images were captured with an IQCAM camera
(Fast1394) using Qcapture Pro 6.0 software. Images were also extracted into Photoshop
(Adobe) to generate the figure 15.
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Table 2: List of S. pombe strains used in the study
Strain

Genotype

Source

YJ374

h+ cds1-6his2HA(int) leu1-32 ura4-D18 ade6-M216

Xu Lab

NW222

chk1-3HA leu1-32 ura4-D18 ade6-M210

Nancy Walworth Lab

Y167

∆rhp51::ura4+ leu1-32 ura4-D18 ade6-M210

Akira Yasui lab

YJ60

cds1-6his2HA(int) leu1-32 ura4-D18 ade6-M210

Xu Lab

NR1826

h- ∆rad3::ura4+ leu1-32 ura4-D18 ade6-M210

P. Russell Lab

TK7

h- leu1-32 ura4-D18 ade6-M210

XuLab

TK48

h+ leu1-32 ade6-M210

XuLab

Table 3: List of Plasmids used in the study
Name

Description

Source

pYJ1339

pIRT-2U+prom+Mus81(SmaI-SphI)ura4+

Xu Lab

pEme1

pWZ118[2U+prom+Eme1+term(SacI-BamHI)]

Xu Lab

Mus81(slx3)

pYJ1339[2U+prom+Mus81(SmaI-SphI)]

Xu Lab

pYJ162

pIRT-2L+prom Mrc[LEU2]

Xu Lab

pYJ283

pIRT-2L+prom Cds1[LEU2]

Xu Lab

Table 4: List of PCR and sequencing primers used in the study
Name
Sequence (5’ -> 3’)

Note

SpMus81(P)SmaI-f

aatgCcCgggtgttacagcgcac

Gene Cloning

SpMus81(T)SphI-b

cagtGCatgcaaaatgcaaaatg

Gene Cloning

Mus81(406-427)f

AGCACGCACAATGAACAGAATG

Sequencing

Mus81(551-528)b

GAATATGCACCAGAACGATAGCTC

Sequencing

Mus81(912-932)f

AAGTTCTTCAGACCACGGAGG

Sequencing

Mus81(1527-49)f

CCGTCATACGCGATCACTTGAAC

Sequencing
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RESULTS

Confirming the drug sensitivity of the fission yeast mutant SN106. A new fission yeast
hus (HU sensitive) mutant was screened in our lab that likely causes a checkpoint defect. This
mutant is SN106. It was identified because it is partially sensitive to HU and UV but highly
sensitive to MMS according to the preliminary results. It was thus predicted to have a mutation
in a checkpoint gene since these mutants are usually sensitive to HU and MMS and the hus
phenotype can be rescued by upregulation of Suc22, the small subunit of ribonucleotide
reductase and the major regulation target of the DNA replication checkpoint. We therefore
decided to investigate further on the SN106 mutant.

We first examined the sensitivities of SN106 to DNA damage by UV, MMS and HU by using
a standard spot assay. Rhp51 is involved in DNA strand break repair thus the rhp51 deletion
strain showed a high sensitivity to UV, MMS and HU (Figure 4A). Rad3 controls both the
DRC and DDC pathways (Yue, 2011) (Figure 1). The deletion strain of rad3 thus cannot grow
on UV, MMS and HU plates (Figure 4A) due to elimination of its checkpoint functions. Chk1
controls the DDC (Figure 1), thus the chk1 mutant showed a high sensitivity to MMS since
MMS induces DNA damage in the G2 phase where the DDC is activated. Since Cds1 is
involved in DRC not DDC, we observed a high killing effect of HU on cds1 deletion strain
since HU induces replication stress in the S phase where DRC is activated. The SN106 mutant
under similar conditions showed a higher sensitivity to MMS and not to HU similar to that
observed in the chk1 deletion strain (Figure 4A). We thus assumed the mutant might be
involved in DDC pathway since Chk1 is involved in the DDC.
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We next examined the sensitivity of the SN106 mutant to DNA damage caused by BLM and
CPT (Figure 4B). The rhp51 mutant was also sensitive to BLM and CPT. The rad3 mutant
showed a high sensitivity to CPT and a partial sensitivity to BLM. The cds1 mutant showed
a decreased sensitivity on CPT and BLM plates (Figure 4B) as it showed with HU in figure
4A. Contrarily, the chk1 mutant showed higher sensitivity on CPT and BLM (Figure 4B)
similar to what was observed with MMS indicating that most of the DNA damage that occurs
at G2, the major cell cycle stage in S. pombe, is mainly dealt by the DDC mediated by Chk1.
The SN106 mutant was also highly sensitive to MMS and BLM similar to the sensitivities in
the chk1 mutant. This result again suggests that the SN106 mutation might be involved in the
DDC. The SN106 mutant also showed a high sensitivity to BLM similar to the rhp51 deletion
strain. Therefore, the mutation may not only affect the DDC but may also affect DNA repair
since Rhp51 is involved in DNA strand break repair as mention earlier.

15

7A
.

7B
.

Figure 4: Drug sensitivity of the SN106 mutant.
A. 10-fold dilutions of the cells were spotted on YE6S plates (Control) or YE6S plates containing
UV, MMS or HU at the indicated concentrations. The wild type YJ374 cells and the deletion
strains of rad3 (NR1827), cds1 (YJ60), rhp51 (Y167) and chk1 (NW222) were used as the
controls. The plates were incubated at 30 °C for 3 days and then photographed.
B. The strains used in A were spotted on YE6S plates (Control) or YE6S plates containing CPT
or BLM at the indicated concentrations.
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SN106 mutant carries a single missense mutation in mus81. To identify the mutated gene,
we transformed the SN106 mutant with S. pombe fork protection library (FPL) to screen
colonies with conferred resistance to HU and MMS. The FPL consists of 17 genes that
function in fork protection cloned in our lab. The vector used for our FPL carried ura4 marker
so the transformed cells were grown on plates lacking uracil and then replicated onto plates
containing HU and MMS. Plasmids were recovered from the yeast colonies with the conferred
resistance to HU and MMS. These plasmids were digested with Hind III restriction enzymes
followed by an agarose gel electrophoresis to study the pattern of the bands obtained. Plasmids
obtained were compared with the typical bands in the FPL and the bands matched to 2 genes;
mus81 and eme1 in the FPL (Figure 6A&B). The SN106 mutant was shown to be fully
rescued by mus81 and partially by eme1 (Figure 7). Under similar spot assay condition in
figure 4A&B, the SN106 mutant transformed with mus81 and eme1 showed resistance to HU,
MMS and BLM (Figure 7A&B).

Since mus81 was confirmed to be responsible for conferring MMS resistance in the SN106
mutant, primers were designed for cloning the mus81 gene (Table 4). Genomic DNA of the
SN106 mutant was extracted for PCR using the designed primers and amplified using the high
fidelity Phusion DNA polymerase. The PCR product was analyzed by agarose gel
electrophoresis and purified DNA sequencing. The DNA sequencing identified a single C-toT missense mutation that changed Arg412 to Cys amino acid in Mus81 (Figure 8). We hereafter
renamed the SN106 mutant as mus81-1. We aligned S. pombe mus81 amino acid sequence to
to the sequences of Mus81 homologs in other eukaryotic organisms. The result showed that
the mutated Arg412 residue in the mus81-1 mutant is highly conserved in rats, mouse, humans,
zebra fish as shown in figure 9.
17

Figure 5: Drug sensitivity of the SN106 mutant transformed with FPL.
This figure represents a replica of SN106 transformation with the FPL grown on YE6S
media containing 5 mM HU or 0.03% MMS. Plasmids were recovered from the larger
growing colonies on the MMS plate and digested with HindIII enzyme to identify the genes
rescuing the mutant. The red dye seen on the plate is the lethality dye phloxin B. It helps
to identify the resistant colonies.
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7A
.

7B.

Figure 6: Restriction analysis of plasmids using enzymes Hind III.
A) The plasmids obtained from resistant colonies were digested with Hind III and run on
agarose gel electrophoresis. Plasmids #1 to #4 likely contain mus81 because of the
similar band patterns. Similarly, plasmid #6 likely carries eme1 gene.
B) The FPL bands were also obtained by diagnostic digestion with Hind III. These bands
were studied and compared with the recovered plasmids shown in A.
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The SN106 mutant is fully rescued by Mus81 and partially rescued by Eme1

Figure 7: Drug sensitivity of the SN106 mutant transformed with plasmids
expressing wild type mus81 and eme1.
HU and MMS sensitivity of the SN106 mutant transformed with mus81 and eme1 plasmids
were assessed by spot assay and compared with wild type, rhp51, chk1, cds1 and rad3
deleted strains.
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Figure 8: Identification of the single missense mutation in the SN106 mutant by
DNA sequencing.
DNA sequencing of mus81 cloned from SN106 revealed a single C-to-T mutation that
causes R412C amino acid change in Mus81.
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Figure 9: Alignment of Mus81 with its homologous proteins in other organisms.
The amino acid sequences of S. pombe Mus81 and its homologous proteins from mouse,
rat, zebrafish, humans were aligned. The residue marked with asterisk is the mutated
Arginine (R) residue that is highly conserved from yeast to humans.
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The mutation in mus81-1 abolishes the nuclease activity of Mus81 in humans. Our mus811 mutation on R412 in S. pombe corresponds to R355 in human Mus81 (Figure 9). The
nuclease domain in human Mus81 binds to the minor groove of DNA through alpha 3 helix
(Gwon et al., 2014) (Figure 3) where the positively charged residues including R355 residue.
In the work of Gwon et al., 2014, mutation that changed R355 to glutamate in alpha 3 helix
almost completely eliminated the nuclease activities toward nicked Holliday junction and the
3’ flap DNA substrates.

(Gwon et al., 2014)
Figure 10: Nuclease activities of various human Mus81-Eme1 mutants
A. Mus81 complex examined toward a nicked HJ. Various hMus81-Eme1 proteins (2
nM) were incubated with a substrate DNA (20 nM) at 37°C for 2, 8, 20, and 60 minutes.
Note, the mutant proteins containing the R355E mutation eliminated the incision activity.
B. Nuclease activities of mutants examined toward a 3’ flap DNA as in A. The R355E
mutation also elminated the nuclease activity.
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The mus81-1 mutant has a moderate DRC defect. Since Mus81 physically binds to Cds1,
the effector kinase for the DRC (Boddy et al., 2000) and genetically interacts with Crb2, the
mediator for the DDC (Kanoh et al., 2003), we examined if the identified mutation disrupts
the checkpoints by examining the phosphorylation levels of Mrc1, Cds1 and Chk1, the major
checkpoint proteins in the DRC and DDC pathways.
We first examined the Mrc1 phosphorylation since Mrc1 serves a mediator of the DRC in S.
pombe (Figure1). The cells were treated with 15 mM HU for 3 hrs and phosphorylation
levels were detected by Western blot with the phosphor-specific antibody as described in the
Materials and Methods. Wild-type cell was used as the control and it showed a robust Mrc1
phosphorylation after 3 h treatment with HU (Figure 11A). The rad3 deletion mutant
showed an undetectable level of Mrc1 phosphorylation as expected (Figure 11A). The
decreased protein level and phosphorylation of Mrc1 in the rad3 mutant is consistent with
the lack of DRC because the activated DRC positively regulates the expression of Mrc1
(Figure 1). In mus81-1 mutant, we identified an increase protein level and the Mrc1
phosphorylation but lower as compared to the level seen in WT cells, indicating a minor
DRC defect (Figure 11A).
We then examined Mrc1 phosphorylation in mus81-1 treated with 0.01% MMS for 90 mins.
The WT cells showed some level of Mrc1 activation after the 90 mins (Figure 11B). The
mus81-1 mutant however showed little to no Mrc1 phosphorylation level after the 90 mins.
To confirm this result, we examined Mrc1 phosphorylation at 30 minutes intervals (Figure
11C). In the WT, we observed a significant activation of the DRC with Mrc1
phosphorylation at 60 mins (Figure 11C). In mus81-1 mutant however we saw little to no
Mrc1 phosphorylation until 120 mins indicating a significant delay in the DRC activation in
the mutant compared to that in WT cells (Figure 11C).
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We also examined phosphorylation of Cds1, the effector kinase for DRC, after treatment
with 0.01% MMS for 90 min (Figure 12). For this purpose, we tagged Cds1 with HA tag
and used anti-HA antibody agarose beads to pull down Cds1 from the cell lysates. Untagged
strain was used as the control. WT cells showed robust Cds1 phosphorylation after the
MMS treatment (Figure 12). As expected, rad3 mutant showed no phosphorylation of Cds1
as its DRC has been eliminated. The phosphorylation of Cds1 in mus81-1 was significantly
decreased as compared to that in WT cells (Figure 12), which also indicates a DRC defect.
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Figure 11: Mrc1 phosphorylation in mus81-1 mutant treated with HU or MMS.
A. Cells were treated with 15 mM HU for 3 hrs. Mrc1 phosphorylation was detected by Western
blotting using phospho-specific antibody. Wild-type and rad3 cells were used as the control.
B. The cells used in A treated with 0.01% MMS for 90 minutes before the examination of Mrc1
phosphorylation.
C. Mrc1 phosphorylation was examined in cells were treated with 0.01% MMS for at 30 minute
time intervals.

26

Figure 12: Cds1 phosphorylation in mus81-1 mutant treated with MMS.
Cells were treated with 0.01% MMS for 90 minutes. Cds1 tagged with HA was
immunoprecipitated with anti-HA antibody beads from the cell extracts. Untagged wildtype cell, WT and rad3 cells were used as the controls.
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The mus81-1 mutant has a moderate DDC defect. To see whether mus81-1 affects the
DDC, we examined the phosphorylation of Chk1, the effector kinase in the DDC pathway.
We treated the cells with 0.01% MMS for 90 mins. We confirmed the HA tagged Chk1 by
Western blotting and then examined the phosphorylation using IP as described in Materials
and Methods. Untagged strain was used as a control. WT cells showed a significant increase
in Chk1 phosphorylation (Figure 13A). The mus81-1 cells however showed a decreased
Chk1 phosphorylation compared to that in WT cells (Figure 13A). To confirm this result,
we examined Chk1 phosphorylation at 30 mins increasing time interval up to 120 minutes
(Figure 13B). The mus81-1 mutant also showed decreased phosphorylation levels of Chk1
compared to the WT cells. Quantitation results confirmed reduction of Chk1
phosphorylation in mus81-1 (Figure 13B).
With these results obtained, we surmised that the observed DRC defect could rather be due
to a delay of the cell cycle at G2 in the presence of DNA damage. To ascertain these
observations, we next monitored cell cycle progression by flow cytometer in the presence of
0.01% for MMS for 120 mins (Figure 14). In the WT cells, we observed a decrease in the
2C DNA content peak after 60 min indicating that the cell had repaired the MMS induced
DNA damage and moved into the S phase (Figure 14). In contrast, the rad3 mutant ignored
the damage and moved into the S phase because it has no checkpoint activation (Figure 14).
The cells however got stuck in the S phase as seen in its 1C DNA content peak. Surprisingly
we observed an increasing number of cells in the S phase in mus81-1. The cells ignored the
MMS induced DNA damage at the G2 phase and continued to the S phase only after 30
mins. We concluded that this result might suggest a DDC defect.
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To confirm the observed DDC defect, we monitored cell division by examination of cells
under microscope to see whether there are any morphological defects. We stained the cells
with Hoechst for genomic DNA and Blankophor for septum and examined cell septation
during the course of 0.01% MMS treatment. In WT cells, cell division was delayed until
after 60 min, suggesting checkpoint activation during the 60 min where the cell cycle was
delayed to repair the DNA damage (Figure 15). Rad3 mutant however underwent cell
division with “cut” cell phenotypes right from time 0 to 120 mins showing short cells
(Figure 15). In contrast, mus81-1 mutant showed longer cells suggesting the cells remained
in G2 for longer time due to delay in G2 because of the defect in DNA repair. This result
suggests that although DDC is activated in mus81-1, a moderate DDC defect may allow the
cells to move onto the next cell cycle.
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Figure 13: Chk1 phosphorylation in the mus81-1 mutant.
A. The cells were treated with 0.01% MMS for 90 minutes. Chk1 was tagged with HA
epitope and pulled down from the cell lysates using anti-HA antibody beads and detected
with anti-HA antibody. The cell extracts prepared were from an equal number of cells.
Untagged cells, wild-type and rad3 cells were used as the controls.
B. Chk1 phosphorylation was examined in cells were treated with 0.01% MMS at 30 minutes
time intervals.

B. Chk1 phosphorylation of mus81-1 with 0.01%MMS at different time. Phosphorylation
level of cells was examined under similar conditions as in A.

30

Figure 14: FACS analysis of mus81-1 mutant in the presence of MMS.
Cells were treated with 0.01% MMS for 120 minutes. During the course of the treatment,
cell cycle progression was monitored by flow cytometry every 30 min.
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Figure 15: Double staining analysis of mus81-1 treated with 0.01% MMS.
Cells stained with Hoechst for genomic DNA and Blankophor to examine cell
septation during the course of MMS treatment for 120 mins.
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Overexpression of Cds1 and Mrc1 in mus81-1 does not suppress drug sensitivity. Since
we observed the DDC defect, we next examined if overexpression of some checkpoint genes
could rescue or suppress the mutation upon treatment with the DNA damaging agents. We
transformed the mus81-1 mutant with mrc1 and cds1 plasmids and performed drug sensitivity
test (Figure 16). WT cells were used as control that was resistant to all the drugs I used
whereas rad3 mutant showed sensitivity to all the drugs since its checkpoint has been
eliminated. Overexpressing Mrc1 and Cds1 in mus81-1 did not significantly rescue the
mutation confirming the mutation may not have a direct effect on the DRC (Figure 16).

Figure 16: Overexpression of Cds1 and Mrc1 in mus81-1 mutant
Mus81-1 mutant was transformed with plasmids expressing Cds1 or Mrc1. The
transformed cells were assessed with drug sensitivity spot assay and compared with
WT and rad3 deleted cells to examine if an increase in the protein levels of Cds1 and
Mrc1 in mus81-1 mutant can partially or fully rescues the mutant from HU, MMS and
UV.

B. Chk1 phosphorylation of mus81-1 with 0.01%MMS at different time.
Phosphorylation level of cells was examined under similar conditions as in A.
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DISCUSSION
In this study, we characterized a potential checkpoint mutant SN106 in fission yeast
that showed a dramatic sensitivity to DNA damage caused by MMS. The drug sensitivity test
performed confirmed that the hypersensitivities of SN106 to MMS, CPT, BLM and not to HU
(Figure 4A & 4B). Similar observations were made with chk1 mutant as it also showed a high
sensitivity to MMS and not HU. We thus assumed the mutant might be involved in the DDC
pathway since Chk1 is involved in the DDC pathway. The SN106 mutant also showed a high
sensitivity to BLM similar to the observation made with the Rhp51 deletion strain. It is
possible that the mutation may also affect DNA repair since Rhp51 is involved in strand break
repair.
Next, we identified a single point mutation in mus81 that causes R412C amino acid
substitution in the SN106 mutant and therefore renamed the mutant as mus81-1 (Figure 8).
As previous studies have revealed the DNA repair activity of Mus81 through homologous
recombination (HR), we predicted the identified mutation to be the cause of the sensitivity of
the mutant to DNA damaging agents particularly to MMS. The dramatic cell killing effect
observed in SN106 by MMS but not HU is due to the fact that MMS induces DNA damage
at the G2 phase that requires repair through the HR pathway. A study confirms that cells
deficient in recombination by Mus81 are hypersensitive to MMS and other agents that induce
strand breaks (Lundin, 2005). Mus81 sequence alignment revealed that the mutated arginine
residue is highly conserved from yeasts to humans (Figure 9). An earlier study showed that
mutation of this residue in combination with other mutations in human Mus81 resulted in the
significant loss of nuclease activities towards both Holliday junction and 3’ flap substrates
(Figure 10). Therefore our mutated residue is likely to be involved in the nuclease activity of
Mus81 in S. pombe. We also assumed that since arginine is a positively charged residue that
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may provide bonding to a negatively charged phosphate group in DNA, the mutation to
cysteine, could also cause destabilization of the protein/DNA structure thus decreasing the
nuclease activity of the protein. This likely explains the cytotoxicity of the mus81-1 mutant
to the DNA damaging agents.
We observed a severe DRC defect in mus81-1 (Figure 11A, 11B, 11C & 12). Further
studies showed however that this observed DRC defect likely caused by the G2 cell cycle
delay. Since the major cell cycle time in fission yeast is the G2 phase, most of the DNA
damage would occur in the G2 phase of an asynchronized cell population. Once the DNA
damage is repaired, the cell would then proceed to the S phase where the DRC can be
activated. If DNA repair is delayed or fails to take place in the G2 phase, the cells will be held
in this phase for a longer time until the repair is finished. With this understanding we attributed
the DRC defect to the cycle delay in the G2 phase because of the defect in DNA repair.
Monitoring the cell cycle progression by flow cytometry and microscopy confirmed this
assumption. However, an increased number of cells in the S phase in the presence of MMS
suggests although the DDC is activated in mus81-1, there might be a minor defect in the DDC.
Chk1 phosphorylation analyses confirmed this minor DDC defect in mus81-1 (Figure 13).
Because the mutation causes a defect in DNA repair, the MMS-treated mus81-1 mutant cells
significantly elongated due to cell cycle delay at G2 phase.
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CONCLUSION
In this study, we identified a new mutation in the fission yeast mus81, a highly conserved
gene in eukaryotes involved in DNA repair. The mutated amino acid residue is involved in
the nuclease activity of Mus81 thus disrupted DNA repair and sensitizes the fission yeast
cells to HU, UV, CPT and particularly to MMS and BLM. The mutation also causes a
moderate defect in the DDC pathway. The effect of this mutation on DNA repair and the DDC
is meaningful as they crosstalk during the process of DNA repair. It is however still unclear
if the mutation has a direct effect on the DRC although the cell cycle delay at G2 explains the
observed DRC defect. Further characterization of this mutant may provide a better
understanding of its checkpoint defects and its cell killing mechanisms with DNA damaging
agents particularly to MMS and BLM. Further studies should also be done to identify
suppressor genes of this mutation. The mus81-1 mutant may also be used as a study model in
cancer biology as the Arginine to Cysteine change accounts for, or are commonly found in
most cancers (Tsuber et al., 2017). This study showed that all single nucleotide mutations in
about two thousand proteins in more than 18,000 cancer samples results from mutations that
cause amino acid change from arginine to cysteine, histidine or tryptophan especially in the
key tumor suppressor proteins (Tsuber et al., 2017) which explains that an increase in arginine
substitutions in cancer is attributed to a high rate of mutation in four of the six codons and
also the high rate of deamination in cytosine resulting in an increased C-to-T nucleotide
substitutions. Lastly, the study on mus81-1 mutant may be informative to cancer
chemotherapy as previous studies have reported that the downregulation of Mus81 sensitizes
cancers to chemotherapy (Zhong et al., 2019; Wu et al., 2011).
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